No new safety findings were observed. The most common treatment-emergent adverse events (>10 percent) occurring more ...

Medically reviewed by Oliver Eng, MD Alanine aminotransferase (ALT) is an enzyme primarily found in your liver. An enzyme is ...

Hepatocellular carcinoma, a type of liver cancer, is the sixth most common cancer worldwide and the third leading cause of ...

Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company developing novel small molecule therapeutics ...

The combination of THIO and Libtayo has shown promising results among patients with advanced checkpoint inhibitor-resistant ...

Researchers provided recommendations for managing adverse events in patients with renal cell carcinoma receiving cabozantinib and nivolumab.

Immunocore reports third quarter financial results and provides a business update KIMMTRAK® (tebentafusp-tebn) net revenues of $80.2 million in 3Q 2024, 28% growth over 3Q 2023 Phase 3 trials in ...

Citi analyst David Lebowitz maintained a Buy rating on Cogent Biosciences (COGT – Research Report) today and set a price target of ...

Rigel Pharmaceuticals, Inc. , a commercial stage biotechnology company focused on hematologic disorders and cancer, today announced upcoming presentations of six posters highlighting data from their ...

The APEX abstract in advanced systemic mastocytosis, or ASM, disclosed one incremental patient discontinuation due to ALT/AST elevation, but the firm notes the 28% rate of ALT/AST increase continues ...

Proceeds expected to support the upcoming planned launches and fund the continued development of Niktimvo and revumenibExpected to fund Syndax through profitability; proforma cash approaching $800 mil ...

The fibrinogen-to-albumin ratio (FAR) is an independent risk factor for development of any preeclampsia (PE) and PE with severe features.